UroGen Pharma Announces Departure of CFO and Appointment of New CFO

On October 7, 2024, UroGen Pharma Ltd. (NASDAQ: URGN) entered into a separation agreement with Don Kim, resulting in his resignation from the positions of Chief Financial Officer, principal financial officer, and principal accounting officer, effective October 8, 2024. As per the terms of the Separation Agreement, Mr. Kim will provide part-time consulting services to the company until April 28, 2025, in exchange for a cash payment of $36,260. His outstanding equity awards will continue to vest during this consulting period.

In connection with this departure, UroGen Pharma appointed Christopher Degnan as the new Chief Financial Officer, principal financial officer, and principal accounting officer, effective on the same date. Prior to joining UroGen Pharma, Christopher Degnan held various senior financial roles in biopharmaceutical and pharmaceutical companies including Galera Therapeutics, Inc., Verrica Pharmaceuticals Inc., and Endo International plc.

Christopher Degnan’s Employment Agreement with UroGen Pharma outlines his initial annual base salary of $500,000 along with eligibility for an annual discretionary performance bonus. Additionally, upon commencement of his role, Mr. Degnan received equity awards, including an option to purchase 74,142 ordinary shares and 13,450 restricted stock units, which will vest over three years subject to his continuous service.

The Employment Agreement also details the terms of potential severance benefits for Mr. Degnan in case of termination without cause, resignation for good reason, death, disability, or in connection with an acquisition of the company. Such benefits include salary continuation, bonus payments, accelerated vesting of equity awards, and reimbursement for COBRA premiums.

These executive changes were disclosed in an 8-K SEC filing by UroGen Pharma on October 9, 2024. The full details of the Separation Agreement and Employment Agreement can be found in Exhibits 10.1 and 10.2 of the filing, respectively.

Investors and stakeholders are advised to refer to the complete text of these agreements for a comprehensive understanding of the terms and conditions associated with the departure of Don Kim and the appointment of Christopher Degnan within UroGen Pharma.

This news release is the official announcement made by UroGen Pharma Ltd. as required by the Securities and Exchange Commission.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read UroGen Pharma’s 8K filing here.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.